Ditolylguanidine

Ditolylguanidine
Clinical data
ATC code none
Identifiers
CAS Number 97-39-2 YesY
PubChem (CID) 7333
IUPHAR/BPS 6684
ChemSpider 7056 YesY
ChEMBL CHEMBL282433 YesY
ECHA InfoCard 100.002.344
Chemical and physical data
Formula C15H17N3
Molar mass 239.316 g/mol
3D model (Jmol) Interactive image
  (verify)

Ditolylguanidine is a sigma receptor agonist.[1] It is selective for sigma receptors, but non-selective between the two sigma receptor subtypes, binding to both σ1 and σ2 with equal affinity.[2] It has neuroprotective[3] and antidepressant effects,[4] and potentiates the effects of NMDA antagonists.[5]

See also

References

  1. Weber E, Sonders M, Quarum M, McLean S, Pou S, Keana JF (November 1986). "1,3-Di(2-5-3Htolyl)guanidine: a selective ligand that labels sigma-type receptors for psychotomimetic opiates and antipsychotic drugs". Proc. Natl. Acad. Sci. U.S.A. 83 (22): 8784–8. doi:10.1073/pnas.83.22.8784. PMC 387016Freely accessible. PMID 2877462.
  2. Glennon, RA (2005). "Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the "deconstruction-reconstruction-elaboration" approach". Mini reviews in medicinal chemistry. 5 (10): 927–40. doi:10.2174/138955705774329519. PMID 16250835.
  3. Katnik, C; Guerrero, WR; Pennypacker, KR; Herrera, Y; Cuevas, J (2006). "Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia". The Journal of Pharmacology and Experimental Therapeutics. 319 (3): 1355–65. doi:10.1124/jpet.106.107557. PMID 16988055.
  4. Skuza, G; Rogóz, Z (2003). "Sigma1 receptor antagonists attenuate antidepressant-like effect induced by co-administration of 1,3 di-o-tolylguanidine (DTG) and memantine in the forced swimming test in rats". Polish journal of pharmacology. 55 (6): 1149–52. PMID 14730114.
  5. Monnet, FP; Morin-Surun, MP; Leger, J; Combettes, L (2003). "Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons". The Journal of Pharmacology and Experimental Therapeutics. 307 (2): 705–12. doi:10.1124/jpet.103.053447. PMID 12975497.


This article is issued from Wikipedia - version of the 5/29/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.